You are here: Industry Insights > Asthma

News List

Report shows less asthma attacks in US children pharmaceutical-technology
February 08, 2018
A new report by the US Centers for Disease Control and Prevention (CDC) has shown that children with asthma are having fewer attacks and less visits to the hospital.
Teva’s subcutaneous asthma drug fails in PhIII pharmatimes
January 24, 2018
Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.
Asthma carves $82 billion out of US economy every year pharmafile
January 16, 2018
A study created by researchers at the Centers for Disease Control and Prevention has estimated that asthma is costing the US economy $81.9 billion each year.
NICE issues new recommendations for asthma care biospectrumasia
December 04, 2017
The recommended objective tests include spirometry and FeNO.
AZ’ Fasenra gets US nod for eosinophilic asthma pharmatimes
November 16, 2017
AstraZeneca’s biologic Fasenra has picked up its first global approval in the US as a treatment for severe, eosinophilic asthma, a difficult to treat form of the condition.
AZ’ experimental asthma drug fails in Phase III pharmatimes
November 03, 2017
An experimental therapy being developed by AstraZeneca and its biologics research and development arm MedImmune has failed to hit key targets in two Phase III trials.
Sanofi, Regeneron’s biologic shines again in asthma trial pharmatimes
November 02, 2017
Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
SingHealth, Duke NUS and GSK join forces for study on asthma and COPD in Singapore biospectrumasia
October 18, 2017
Singapore has one of the highest asthma prevalence rates in the world, with around one-in-five children and five per cent of adults diagnosed with the condition
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benr worldpharmanews
September 13, 2017
AstraZeneca has announced results from a subgroup analysis of the SIROCCO and CALIMA Phase III trials.
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with sever worldpharmanews
September 07, 2017
AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe,

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page